Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - gabapentin -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lamotrigine, quantity: 200 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; maltodextrin; calcium carbonate; flavour - lamidus is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lamotrigine, quantity: 100 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - lamidus is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lamotrigine, quantity: 50 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - lamidus is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lamotrigine, quantity: 25 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - lamidus is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.